Recent 8-K filings for ATXI
Highest-materiality recent filing
Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets
- Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
- Delisting due to failure to maintain minimum $2.5M stockholders' equity per Nasdaq Rule 5550(b)(1).
-
Exclusive worldwide license from Duke for ATX-04 (clenbuterol) to treat Pompe disease as adjunct to ERT.
-
Avenue Therapeutics shareholders elect all six director nominees and ratify KPMG as auditor
All six director nominees elected: Jay Kranzler, Faith Charles, Neil Herskowitz, Alexandra MacLean, Curtis Oltmans, Lindsay Rosenwald.
-
Avenue Therapeutics sets Dec 30, 2025 annual meeting; Nov 28 deadline for proposals
Annual meeting scheduled for December 30, 2025; proxy statement to be filed with SEC.
-
Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.
-
Avenue Therapeutics terminates AJ201 license; gets $2M cash, up to $24M milestones, 1.75% royalty
License terminated; all AJ201 rights and assets transferred back to AnnJi; mutual releases and dismissal of disputes.
-
Nasdaq to delist Avenue Therapeutics on March 19; stock to trade on OTC Markets
Nasdaq notified Company it will delist common stock effective at open on March 19, 2025.
-
Nasdaq Panel granted continued listing subject to: public disclosure by Mar 14, fundraising update by Mar 14, AJ201 trial results by Apr 15.
Materiality & sentiment trend
Max materiality 0.90 · Median 0.75 · Most common event other_material